Indaptus Therapeutics, Inc. Income Taxes Paid
Indaptus Therapeutics, Inc. (INDP) reported Income Taxes Paid of $1.60 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2025-03-13
- Indaptus Therapeutics, Inc. income taxes paid, net for the quarter ending 2023-12-31 was $0.00.
- Indaptus Therapeutics, Inc. income taxes paid, net for the quarter ending 2023-09-30 was $0.00.
- Indaptus Therapeutics, Inc. income taxes paid, net for the quarter ending 2022-12-31 was $0.00.
- Indaptus Therapeutics, Inc. income taxes paid, net for the quarter ending 2022-09-30 was $0.00.
- Indaptus Therapeutics, Inc. income taxes paid, net for fiscal 2024 was $1.60K, a 0.00% change from fiscal 2023.
- Indaptus Therapeutics, Inc. income taxes paid, net for fiscal 2023 was $1.60K, a 33.33% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. income taxes paid, net for fiscal 2022 was $2.40K, a 200.00% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. income taxes paid, net for fiscal 2021 was $800.00.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.60K 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $1.60K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.60K 10-Q · filed 2023-11-06 | ||
| 2023-06-30 | $1.60K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $2.40K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.40K 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $2.40K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$9.20K derived: sum of 2 quarters · filed 2023-03-17 | $800.00 10-K · filed 2023-03-17 | |
| 2021-09-30 | -$9.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $800.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $10.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |